SCHEMBL4480759

SCHEMBL4480759

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)[C@H](C(=O)Nc2cccc(Cn3ccnc3)c2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.49
JAK1 P23458 1/20 0.49
USP30 Q70CQ3 1/20 0.45
SIRT2 Q8IXJ6 2/20 0.44
S1PR1 P21453 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.41
TBXAS1 P24557 1/20 0.40
AGTR2 P50052 1/20 0.40
CYP19A1 P11511 2/20 0.40
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
CCR3 P51677 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ACKR3 P25106 1/20 0.39
HDAC8 Q9BY41 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491921 1.00 JAK2 (0.49) JAK2JAK1USP30SIRT2S1PR1
SCHEMBL13604563 1.00 JAK2 (0.49) JAK2JAK1USP30SIRT2S1PR1
SCHEMBL4489642 0.87 JAK2 (0.45) JAK2JAK1SIRT2S1PR1NPC1
SCHEMBL13604611 0.86 JAK2 (0.49) JAK2JAK1USP30S1PR1NPC1
SCHEMBL13604571 0.86 SIRT2 (0.48) JAK2JAK1USP30SIRT2NPC1
SCHEMBL4490858 0.86 SIRT2 (0.48) JAK2JAK1USP30SIRT2NPC1
SCHEMBL13604610 0.86 JAK2 (0.49) JAK2JAK1USP30S1PR1NPC1
SCHEMBL13604584 0.84 SIRT2 (0.46) USP30SIRT2NPC1RAB9ACCR3
SCHEMBL4489634 0.84 SIRT2 (0.46) USP30SIRT2NPC1RAB9ACCR3
SCHEMBL5927840 0.80 PTPRB (0.43) JAK2JAK1USP30TBXAS1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635697-B2 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases SCHERING CORPORATION (US) 2009-12-22 US disclosed
US-7635697-B2 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases SCHERING CORPORATION (US) 2009-12-22 US disclosed
US-7635697-B2 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases SCHERING CORPORATION (US) 2009-12-22 US disclosed
US-20060211706-A1 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases SCHERING CORPORATION 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211706-A1 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases FNTB, FNTA, FDPS JAK2 3171/4885JAK1 4022/4885USP30 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.